Following the addition of albumin to the test medium at clinically relevant concentrations (0.1%), the extrapolated clinical interpretation of ofloxacin switched from susceptible to intermediate in 5 canine patients (cases #2, #4, #7, #17, and #21), all of whom experienced complications with corneal healing (e.g., progression of corneal ulcer, graft dehiscence). The gene discussed is ALB; the disease is corneal ulcer.